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Background: Cardiovascular disease (CVD) is a major cause of death in China. Despite government efforts, the
majority of hypertensive and diabetic patients in China do not receive proper treatment. Reducing CVD events
requires long-term care that is proactive, patient-centred, community-based, and sustainable. We have designed a
package of interventions for patients at high risk of CVD to be implemented by family doctors based in township
hospitals (providers of primary care) in rural Zhejiang, China. This trial aims to determine whether the systematic
CVD risk reduction package results in reduced CVD events among patients at risk of CVD compared with usual care,
and whether the package is cost-effective and suitable for routine implementation and scale-up.
Methods/Design: This is a prospective, open-label, cluster randomized controlled trial (RCT) with blinded data
analysis. The trial will randomize 67 township hospitals with 31,708 participants in three counties in Zhejiang
Province. Participants will be identified from existing health records and will comprise adults aged 50 to 74 years,
with a calculated 10-year CVD risk of 20% or higher, or diabetes. In the intervention arm, participants will receive a
package of interventions including: 1) healthy lifestyle counseling (smoking cessation, and salt, oil, and alcohol
reduction); 2) prescription of a combination of drugs (antihypertensives, aspirin, and statin); and 3) adherence
support for drug compliance and healthy lifestyle change. In the control arm, participants will receive usual care for
hypertension and diabetes management at individual clinicians’ discretion. The primary outcome is the incidence of
severe CVD events over 24 months of follow-up. All CVD events will be defined according to the World Health
Organization (WHO) monitoring of trends and determinants in cardiovascular disease (MONICA) definitions,
diagnosed at the county hospital or higher level, and reported by the Zhejiang surveillance system. Secondary
outcomes include: mean systolic and diastolic blood pressure, blood glucose, serum total cholesterol (TC), and
adherence to appointments, and drugs and lifestyle changes.
Discussion: This trial focuses on risk reduction of CVD rather than specific diseases. It is not designed to compare
therapeutic and healthy lifestyle interventions, but rather their combined effects in primary care settings. Through
the trial, we intend to understand the effectiveness of the comprehensive CVD reduction package in routine
practice. We also intend to understand the barriers and facilitators to implementing the package, and thus to advise
on policy and practice change.
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Cardiovascular disease (CVD) accounts for 38% of total
mortality in China [1]. The mortality rate for stroke in
China is four to six times higher than that of Japan and
the USA [2]. In 2008, China had 200 million people with
hypertension, 160 million with dyslipidemia, 92 million
with diabetes, and 200 million who were overweight
[1,3]. CVD events are predicted to increase by 23% from
2010 to 2030, resulting in an additional 21.3 million CVD
events and 7.7 million deaths [4].
The majority of people in China with hypertension or
diabetes are not aware of their disease(s) and do not get
proper treatment: a national survey in 2002 showed that
hypertension prevalence increased by 73% between 1991
and 2002; only 23% of hypertensive patients were aware
of their status; of these only 17% were on treatment;
and of those who were treated only 4% had their blood
pressure under control [5]. A national survey in 2008
showed diabetes prevalence was 9.7%; however, the
prevalence of diagnosed diabetes was only 2.7% [3]. A
recent survey found hypertension prevalence in one
rural area of China was 40% [6]. In China, patients with
hypertension, diabetes, and related CVD conditions mostly
receive ad hoc care, they are prescribed medications based
on the family doctor’s knowledge, and many patients
stop taking drugs once they feel well. Patient adherence
to antihypertensive drugs is low, ranging from 20% to
60% [5,6]. The pilot study in Zhejiang suggested that 6%
of rural residents aged between 40 and 75 years had a
10-year CVD risk of 20% or higher [7], and nearly half
of hypertensive or diabetic patients had stopped their
treatment because of a reduction in symptoms in the past
year [7]. Service improvements and sustainable systems
to encourage patient adherence to treatment and healthy
lifestyles are therefore needed.
Meta-analysis has indicated that CVD risk reduction
by treating hypertension or diabetes is not sufficient [8].
A comprehensive approach is needed, based on drug
therapies and lifestyle support in primary care settings
for patients with high CVD risk. Systematic reviews have
shown that antihypertensive drugs will reduce the risk
of stroke by 63% and ischemic disease by 46% [9], while
statins reduce the risk of stroke and ischemic disease
by 60% and 17%, respectively [10]. Meta-analysis confirms
the safety of using aspirin, statins, and antihypertensive
drugs, and that they can reduce CVD risk by 80% [11,12].
Two recent trials of a fixed-dose ‘polypill’ successfully
reduced systolic blood pressure by 6 to 7 mmHg: the
authors predicted that the polypill could reduce coronary
heart disease by 62% and stroke by 48% in the long-term
[13,14]. In addition to drugs, healthy lifestyle counseling
has shown a small-to-moderate effect in reducing multiple
CVD risk factors [15,16], improving patient quality of
life [17], and reducing mortality [18]. A study in Ontario,Canada, reported that a community-based education
program for older people reduced CVD-related hospital
admissions in general by 9% within 10 weeks [19]. A review
in China suggested community-based health education
and management may reduce the stroke rate by 20%
to 30% among the general older population over 3 to
4 years [20]. Salt reduction or substitution leads to re-
duced blood pressure [21], and a study in China re-
ported that salt substitution for 12 months reduced
systolic blood pressure by 3.7 mmHg [22]. Smoking
cessation and increased exercise can be sustained for
10 to 20 years after the intervention [23,24].
Currently, large-scale community-based interven-
tions, such as The Oxford Health Alliance’s Community
Interventions for Health [25], are being implemented in
several countries including China, but not as trials. A trial
using village doctors to provide individual drug manage-
ment and salt consumption reduction is on-going [26].
However, village doctors currently play a very limited role
in chronic disease management due to their low capacity
and because they practice as de facto private practitioners
[27,28]. Furthermore, previous trials have mainly used
blood pressure as the primary endpoint.
Based on information from the China hypertension con-
trol guideline and systematic reviews, we have developed a
package of CVD risk reduction interventions including: 1)
health education on smoking cessation, and salt, oil, and
alcohol reduction; 2) drug therapy using antihypertensives,
low dose aspirin, and a statin; and 3) adherence support to
encourage drug compliance and healthy lifestyle change.
The intervention package is designed to fit within China’s
national package of essential public healthcare. This
trial aims to determine whether the systematic CVD
risk reduction package results in reduced CVD events
among patients at risk of CVD compared with usual care,
and whether the package is cost-effective and suitable for
routine implementation and scale-up. We believe this trial
is the first to use CVD event rates as the primary out-
come; thus it will provide additional evidence to inform
changes in policy and practice.
Methods
Design of the study
This will be a health service delivery trial that combines
screening, treatment, and lifestyle change interventions.
It is designed as a prospective, open-label, cluster ran-
domized controlled trial (RCT) with blinded data ana-
lysis (Figure 1). We conducted two pilot studies prior to
the trial: a pilot study to assess the feasibility of imple-
menting the CVD prevention guidelines in two township
hospitals in Zhejiang; and a pilot implementation in one
township hospital from September 2012 to June 2013 to
examine the feasibility and acceptability of intervention
and research procedures. The results of the two pilot
Figure 1 Trial design flow chart.
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the forthcoming trial.
Setting
The trial will take place in three counties of Shaoxing
Prefecture in Zhejiang Province. Zhejiang is located on the
east coast of China and has a population of 54 million.
CVD is the largest cause of death in Zhejiang: the
population-based percentage of deaths due to CVD
was 1.8% in Zhejiang [29] in 2009, as compared to 2.0% in
China in 2007 [1]. The prevalence rates of the major
CVD risk factors is similar between Zhejiang and China: for
example, the hypertension prevalence was 20% in Zhejiang
[29] and 19% in China [1]; and the prevalence of diagnosed
diabetes was 4.1% in Zhejiang in 2009 [29], similar to
that in China.
Primary care is provided by public township hospitals.
Each township hospital covers 50,000 to 200,000 people.
Family doctors in the township hospitals are responsible
for acute and preventive care, including chronic disease
control, with an average population of 1,500 per family
doctor. Since 2009, Zhejiang has established a chronic
diseases surveillance system, covering all the counties in
the province. Each health facility must report any CVD
events to the Centre for Disease Control and Prevention
(CDC) through this system. This system is checked
daily in CDCs at the provincial, prefectural, and countylevels, allowing easy collection of CVD events within the
administrative boundaries, and elimination of any duplica-
tion of CVD events reported by different health facilities.
Inclusion and exclusion criteria for participants
Inclusion criteria for clusters are: township hospitals that
have electronic health records of their residents for the last
two years; are situated within the three selected counties of
Zhejiang; and have agreed to participate in the trial.
CVD risk will be assessed at enrolment by the Asian
Equation. The Asian Equation was developed using six
cohorts of 172,077 individuals who were followed-up for
20 years in several Asian countries [30], and evaluated
using independent Chinese cohorts. Its discrimination
ability is better than the Framingham Equation. The Asian
Equation calculates an individual’s risk of having any CVD
event in the next 8 years based on gender, age, systolic
blood pressure, total cholesterol (TC), and smoking status,
shown as a percentage from 0% to 100%. In this study,
we revised the Asian Equation to estimate the CVD
risk in the next 10 years to be comparable with other
internationally recognized equations. The Asian Equation
effectively predicts both ischemic and hemorrhagic CVD
events in the Chinese population, while others only pre-
dict ischemic CVD events [31,32]. TC is part of the health
check of all residents aged over 60 years in China. Patients
with diabetes are automatically considered at high risk of
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participants with a high CVD risk using the Asian Equation
and participants with diagnosed diabetes.
Inclusion criteria for participants are: adults aged 50 to
74 years who have provided informed consent; hold per-
manent residence in the study area; and have a calculated
10-year CVD risk of 20% or higher, or a recorded medical
history of diabetes. Diabetic patients are included because
diabetes is a single decisive factor for high CVD risk [33].
Exclusion criteria for trial participants are: patients
with mental health problems or other disabilities which
mean they cannot communicate with family doctors well or
regularly; patients who have had any severe CVD event, in-
cluding acute coronary events, acute myocardial infarction,
and any ischemic or hemorrhagic cerebrovascular events
(identified from the chronic diseases surveillance system),
as they are managed by county hospitals, and often do not
seek care in township hospitals. We will also exclude:
patients with other severe diseases, for example, late
stage cancer; patients who are hospitalized; patients who
have had serious adverse effects to the drugs used in the
trial; patients who have diastolic blood pressure lower than
60 mmHg as they are contraindicated to hypertensive
drugs; patients who are at high risk of CVD but do not have
hypertension (more than 140/90 mmHg) or diabetes, be-
cause they are not routinely treated in township hospitals
(although they will be referred for healthy lifestyle consult-
ation, and further diagnosis if appropriate); and individuals
who decline to participate in the trial.
All study participants will be treated and managed
under their township hospital by their family doctor,
who is responsible for the chronic disease management
of one village. The family doctors will ensure that all
eligible participants from their catchment areas are seen
and recruited at baseline and followed-up.
Usual care
In the control arm, usual hypertension and diabetes
management will continue according to current national
guidelines: conventional clinical consultations; treatment
provision according to existing knowledge and at the
individual clinician’s discretion; no specific adherence
support; and non-systematic health education. Within
usual care, treatment and lifestyle changes are recom-
mended to participants based on either hypertension
or diabetes, but not based on the holistic approach of
CVD risk reduction. Patients with both hypertension
and diabetes often need to attend different consultations
for medications and lifestyle advice.
Intervention
In the intervention arm, participants with a CVD risk
of ≥20% and those with diagnosed diabetes will be pro-
vided, as appropriate, with a systematic CVD risk reductionpackage. Patient addresses and contact numbers are rou-
tinely recorded as part of usual care, and will be used to
trace patients for follow-ups. The intervention activities are
designed to fit within the job descriptions of family doctors
and are detailed in a desk guide. The systematic CVD risk
reduction package comprises: healthy lifestyle education,
drug therapies, and adherence support.
Healthy lifestyle education
Regular health education consultations will be provided
by township hospital family doctors and reinforced monthly
during follow-up appointments. Consultations will include
smoking cessation advice and support, as well as advice on
healthy eating (especially salt and oil reduction) and advice
on alcohol reduction. There is no charge for healthy
lifestyle consultations.
Drug therapies
Drugs prescribed in the intervention will be from the
essential drug list. All patients with hypertension will
be prescribed with a combination of two antihypertensive
drugs, a statin, and a low dose of aspirin. Patients only with
diabetes will be prescribed one antihypertensive drug, a
statin, and a low dose of aspirin, plus their anti-diabetic
drugs. The antihypertensive drugs and aspirin cost around
£0.50 per month. Statins are relatively expensive drugs, for
example, simvastatin costs approximately £10 per month.
In Zhejiang, the rural health insurance scheme covers
30% of outpatient costs. However, patients must pay
the remaining 70% at each consultation. There is no user
fee for patient consultations.
The desk guide to be used in the trial includes a clin-
ical algorithm and information on the use of the recom-
mended drugs, as well as how to replace existing drugs,
if necessary. The guide includes a list of contraindica-
tions and adverse effects for aspirin, statins, and antihy-
pertensives [12,34,35]. The safety profiles of the
individual drugs recommended in the intervention are
well established [11,36,37]. The trial will pose minimal
risks to patients, since drugs will be modified on an indi-
vidual basis.
Adherence support
Participants will meet with their family doctors monthly
either in the township hospitals, health stations
(branches of township hospitals), village clinics, or at a
family doctor home visit. Participants will be referred to
a nurse educator to improve drug adherence initially
monthly and then quarterly. Patient support will draw
on our experience using similar systems for tuberculosis
and antiretroviral treatment adherence [38,39]. A treatment
supporter will be chosen and, together with the patient,
will be advised about their role supporting the patient and
encouraging drug and lifestyle advice adherence. Expert
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clinical appointments will be reminded by mobile phone.
Primary care providers in the intervention arm will be
trained on counseling skills, using role-play in their
training. Refresher training sessions will be provided and
feedback from interventions will be discussed in the
monthly internal meetings of township hospitals. A quality
control plan has been developed and embedded within
the routine essential public health service.
Outcomes
Primary outcome
The primary outcome is the incidence of severe CVD
events over 24 months of follow-up. CVD events are
defined according to the WHO MONICA definitions,
including: 1) acute coronary events; 2) acute myocardial in-
farction, sudden cardiac death, and other deaths due to cor-
onary and vascular disease; and 3) ischemic or hemorrhagic
cerebrovascular events. Minor CVD events, such as chronic
cerebral arteriosclerosis and transient ischemic attacks, are
not included because these events do not usually end in
hospitalization and are often not reported. Participants who
cannot be contacted after three attempts (either by tele-
phone, email, or letter) by 24 months after randomization
will be deemed as lost to follow-up. Person years will be
used to calculate CVD event rates for participants whose
CVD event outcomes are recorded. We will also record the
time of patient contacts in both arms. Since sufficient infor-
mation about CVD events and contact times is available,
the outcome of CVD events and contact times will cover
the last contact time for the loss to follow-up cases and
mortality cases that were not due to CVD events.
Sample size
The intervention is expected to lead to a reduction of at
least 20% in CVD event rates within two years. This is
based on a conservative estimate from the results from
meta-analyses [9,11,18,37], a review of community-based
programs in China [20], and recent trials [13,14,19,40].
According to the baseline of the pilot study, the target
population (aged 50 to 74 years with ≥20% CVD risk and
diabetes) has a CVD incidence rate of 5% within two
years: we use this as an estimate of the CVD event rate in
the usual care arm. In order to detect a 20% difference
between the two arms with 90% power, using two-sided
testing at the 5% level, and a moderate coefficient of
variation (CV) of 0.15 [41] with approximately 450 par-
ticipants per cluster (using harmonic means to adjust
for imbalances in cluster size [42]), we estimate 32 clusters
per arm are needed [41,43].
Secondary outcomes
The secondary outcomes are: 1) mean systolic and diastolic
blood pressures of participants; 2) time to the first reportedCVD event, mortality, and morbidity of CVD events during
the trial period of 24 months; 3) mean change in blood
glucose and glycated hemoglobin (Hb1Ac); 4) mean change
in serum TC and low density lipoprotein; 5) adherence
to booked appointments, using the denominator of all
participants registered, including defaulters; 6) self-reported
adherence to drugs and healthy lifestyle change, for ex-
ample, smoking cessation rates (for participants who smoke
at randomization, the percentage who smoke less than
one cigarette a week at 24 months after randomization);
7) cost-effectiveness; and 8) feasibility measures.
Sample size calculation for secondary outcomes of
blood profiles
Due to resource limitations, we will collect participant
blood samples to measure blood glucose, Hb1Ac, and
lipid profiles only on a subsample of participants. The
survey will be conducted at 0 and 24 months after
randomization. The sample size is based on change in
TC levels and the blood profile indicator is anticipated
to show the smallest change of means (and hence expected
to require the largest sample size). According to the
pilot study, the mean and standard deviation of TC
were 4.48 mmol/L and 0.8526 mmol/L, respectively.
We anticipate a reduction of 6%. In other similar studies,
a TC reduction of 16% to 20% was observed [14,44]. In
the pilot study, a third of participants took statins. We
therefore assume that we will achieve a third of 18% re-
duction in TC, that is, 6% in the intervention arm. We es-
timate that we need to increase the sample size by a factor
of two to allow for clustering, with an intracluster correl-
ation (ICC) of 0.01, and a maximal of 100 participants per
cluster. Clusters will be chosen randomly from each arm
and sampling will be undertaken within the required clus-
ters. With 90% power and using two-sided testing at the
5% level, six clusters are required in each arm, allowing
for a loss to follow-up rate of 10% [42,45].
Randomization
All township hospitals with available health records in the
three countries in Shaoxing, Zhejiang, will be selected
except the pilot site. Written informed consent will be
sought from each township hospital and from each of the
participants in the township hospitals before screening.
Townships will be randomized, without stratification,
to intervention or control in a 1:1 ratio. No blinding will
be performed in this study. The sensitivity analysis shows
that stratified randomization does not significantly raise
the power compared with simple randomization. A study-
independent biostatistician will be responsible for the
randomization pattern generation. Participants will then
be identified according to the inclusion/exclusion criteria.
All participants within each township will receive the care
allocated to their township hospital. For logistical reasons,
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control clusters), then after two months be extended to
the second county, and after four months to the third
county. We expect participant recruitment to take two
months in each county.
Participants will be identified from existing health
records. The pilot study showed that each township
hospital has an average of 500 eligible participants who
may agree to participate in the trial. All eligible participants
identified from existing health records will be asked to visit
the township hospital, and will then be examined by the
family doctor against the exclusion criteria. A well-trained
nurse will consult participants on their willingness to par-
ticipate and obtain informed consent.
Ethical approval
The trial obtained ethical approval from the Research
Ethics Committee of the University of Leeds, UK, on 8
October 2012 (reference HSLTLM/12/010) and the Ethics




CVD events will be collected from the Zhejiang provin-
cial CVD surveillance system at 12 and 24 months after
randomization. The system comprises data on all deaths
and hospitalizations caused by heart disease and ische-
mic or hemorrhagic cerebrovascular disease reported by
all levels of hospitals according to the WHO MONICA
CVD events definition. The provincial CDC validates
the accuracy of the reporting system through surveys on
a regular basis.
In addition to the CVD surveillance system, participants
in both arms will be asked retrospectively about stroke or
heart attack diagnosed by hospitals at the county level
or above at 12 and 24 months after randomization.
Any hospital-confirmed reports would be amended in
the surveillance system.
Secondary outcomes
Blood pressure, attendance rates, and rates of adherence
to drugs will be collected using routine forms already in
use in township hospitals, that is, the hypertensive and
diabetic participant follow-up forms. On enrolment, the
family doctor will measure the participant’s blood pres-
sure using a standardized mercury sphygmomanometer
after 5 minutes of seated rest, and measure body weight
and height using standard measures. We have designed
additional forms to record extra drug use in both interven-
tion and control arms. Any serious adverse events will be
recorded in a separate form during each follow-up consult-
ation. In practice, participants need monthly prescriptions
of drugs because the health insurance scheme only allows asingle prescription to contain 1 month’s supply. Therefore,
participants are likely to visit their family doctors every
month. Adherence to booked appointments will be
measured by examining attendance at booked appoint-
ments. Follow-up forms will be completed every quar-
ter, collected from a computer-based system.
Participants’ blood profiles will be collected using
sample surveys at 0 and 24 months after randomization.
The surveys will comprise: 1) a questionnaire regarding
participant demographics, socioeconomics, lifestyles, CVD
history, current drug therapies if any, health service use,
medical and related costs, and quality of life using the vali-
dated Chinese version of EQ-5D (EuroQol, Rotterdam, The
Netherlands); and 2) a blood sample for measuring blood
glucose and lipid profiles. Blood profiles will be measured
with specifications of the fasting period, and will be
collected according to the procedures outlined in the
National Institutes of Health (NIH) guidelines [46] and
Chinese guidelines [47]. Blood samples will be col-
lected and transferred to the Zhejiang Provincial CDC.
Standardized measurements, such as the enzymatic
method, will be used.
Costing and cost-effectiveness analyses
An economic study from the societal perspective will be
conducted to compare the cost-effectiveness of this inter-
vention with usual care. The costs of the intervention over
and above usual care (excluding research costs) will be
collected, and used together with the above effectiveness/
outcome measures to calculate the incremental cost-
effectiveness ratio. Costs will include capital costs,
such as training, other costs to strengthen the capacity
of providers to deliver enhanced services, and recur-
rent costs, such as drugs and laboratory tests. Doctors’
salaries will not be included as no extra working time
is sought in the intervention. Project record review
and interviews with managers will be conducted to ob-
tain cost data. Participant costs, including costs of
drugs and other treatments, transportation, and loss of
productivity, will be collected through a questionnaire
survey, to be conducted as part of the sample survey at
0 and 24 months after randomization. Hospitalization
and any loss of work days due to CVD events, as well
as time costs associated with participants’ travel and
waiting time will be recorded and converted into mon-
etary forms. Markov models [48] will be used to simu-
late possible future states of the control and treatment
arms, and to capture possible longer-term health out-
comes (for example, additional years of life) and asso-
ciated costs of care.
Process evaluation
A process evaluation will: describe the health system and
service delivery context in which the intervention was
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cluster level (township hospital) and the individual level
(patient); explore whether or not the intervention was
delivered as intended, both at the cluster level (training)
and the individual level (provider delivery); and explore
the responses to the intervention both at the cluster
level (managers and providers) and the individual level
(patients and treatment supporters). Methods will include
document review (for example, recruitment records, meet-
ing minutes), observation of training and consultations, and
interviews (for example, with CDC officials, hospital man-
agers, family doctors, patients, and treatment supporters).
Data will be collected at approximately 6 and 18 months
into the trial. A sampling frame will be developed and
participants will be purposively selected for inclusion
from the above sampling sites.
Analysis
This study is designed as a pragmatic trial of the care
strategies within the primary healthcare context of China,
rather than a therapeutic agent trial per se. Measures will
be taken, however, to ensure a blinded outcome evaluation
using: 1) the ‘PROBE’ design [49]; and 2) blinding those
analyzing the outcome data to treatment status. The
primary and some secondary outcomes are objective
and not affected by participant or provider knowledge
of treatment allocation. The primary outcomes are
CVD events, such as strokes and myocardial infarction,
which are objective outcomes. They are diagnosed by
doctors at the county hospital who are not involved in the
intervention and reported through the internet reporting
system. Patients in both arms will be asked about CVD
events, and non-reported events will be entered into the
reporting system. In addition, the statistician will be blinded
to which is the intervention arm. The secondary outcomes
include drug use and healthy lifestyle endpoints, which may
result in more variables in the intervention arm compared
with the control arm. To avoid this as a leaking sign, we
will generate a set of dummy data for additional health style
endpoints to balance the data of two treatment groups;
therefore, the independent statistician will not be able to
distinguish which group is the intervention arm.
Analysis will be by intention-to-treat as the primary
analysis and then per protocol, and will be conducted at
the cluster level. The primary analysis will be undertaken
on a dataset that includes all participants recruited in the
study. The mean difference between the intervention and
control outcome measures will be calculated. Potential
prognostic factors will be controlled for to assess the effect
of the intervention. In secondary analysis, mortality and
morbidity of CVD events will be analyzed separately.
In addition, the secondary analysis will also explore the
relationship between adherence to drugs and primary
or secondary outcomes. All outcomes will be analyzedat the end of the trial: no formal interim analysis is
planned for this study. Safety data will be reviewed formally
at 6 months of follow-up to ensure participants’ safety and
integrity of the study.
A detailed data analysis plan is provided in Additional
file 1.
Discussion
Reducing CVD events requires long-term care that is pro-
active, patient-centred, community-based, and sustainable
for patients with hypertension, diabetes, and related CVD
conditions. Equitable delivery at a feasible cost is only pos-
sible through systems based on primary care [50,51]. The
challenge, as outlined in the WHO package of essential
non-communicable disease interventions [52], is how to
implement a systematic, feasible, and effective model for
primary healthcare in low resource settings.
This trial is not designed to compare therapeutic and
health lifestyle interventions, but rather their combined
effects within the context of China’s health policy and
practice. Specific effects of either therapeutic and lifestyle
interventions have been well documented in the literature.
Rather, we will test the combined effects in realistic pri-
mary care practice as a pragmatic trial. Adherence rates
will be a secondary outcome. We expect lower adherence
rates for statins owing to their high cost. The sample size
has been adjusted to detect a relatively small change of
CVD risk due to possibly smaller numbers of patients
agreeing to take the preventive drugs, and so would be the
compliance rates of drugs (compared with the more usual
hospital-based drug trials).
The is the first trial to date in developing countries to
synthesize all current evidence on therapeutic and healthy
lifestyle interventions to prevent CVD events in a primary
care setting. Previous CVD prevention programs were
mostly conducted through teaching hospitals in urban
settings with very limited involvement of rural township
hospitals (the primary care providers in rural China)
[53]. A recent trial implemented by the George Institute
in China differs from this one in terms of the population
studied, drugs used, lifestyle intervention, and primary out-
come (blood pressure rather than CVD rate reduction).
The interventions fit within China’s national health reform
programs, which are designed to strengthen primary
care, essential public health tasks, and the rural health
insurance scheme.
Through the trial, we hope to understand the barriers
and facilitators that affect CVD control, and assess how
to overcome implementation challenges and scale-up the
package. Outputs will include a case management guide,
training modules, and other materials that may be scaled-
up in Zhejiang Province and other parts of China. These
study materials also have the potential to be adapted to
other low/middle income countries.
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of the drugs and lifestyle advice prescribed. Challenges
from both the participant and provider perspectives
need to be addressed. The first challenge is related to
the cost of medication. Drugs recommended in this trial
are commonly available in primary healthcare practice
in China. However, patients need to co-pay 70% of the
cost of these drugs [54]. The cost challenge, especially
due to the combined medication, may be offset by the
increasing health awareness of chronically ill patients. A
study in 2006 found that the majority of Chinese people
believed that antihypertensive drugs were beneficial,
and were willing to pay £50 per year to reduce a 5-year
CVD risk of 35% or higher [55]. Furthermore, we estimated
a smaller effect size for the pragmatic trial compared with
that from hospital-based drug trials. The second challenge
is people’s misperception of their health. The pilot study
showed some participants were reluctant to take medicine
or stopped medication when their symptoms diminished.
This challenge can be addressed through regular health
education and family treatment supporters in the interven-
tion design. The third challenge is related to the primary
healthcare providers’ capacity to implement the interven-
tions. This will be addressed through innovative training
sessions, such as participatory training, as well as training
using the opportunity of routine refresher training sessions
in the township hospitals. The quality of the trial will be
ensured through enhanced supervision activities from
the county’s CDC. The expected increase in prescription
and regular use of preventive drugs in the intervention
group will increase the risk of adverse effects, but in a
population with a high CVD risk, the benefits outweigh
the risks [11,36]. The family doctors will closely monitor
the adverse effects based on the specific guidelines. Any
serious adverse events will be documented and referred
to county hospitals.
In both control and intervention sites, CVD events are
diagnosed in hospitals at county level and above. All
county or above hospitals use the same diagnostic guide-
lines required by the provincial CVD surveillance system.
Given incomplete reporting of the electronic reporting sys-
tem (currently missing around 10% to 15%), we will match
reported CVD events against individuals enrolled in
the trial using the health insurance number as the uni-
fied identifier. This will also be triangulated through
participant-reported CVD events in both arms.
Trial status
At the time of submission of the manuscript, the pilot
study had just finished. The trial will start in September
2013 and the participants will be recruited during the first
2 months, September and October 2013. It is expected that
the trial will last 24 months. The Trial Steering Committee
and the Data Management and Ethical Committee of thetrial were set up in June 2013. The sponsor of the trial is
the China Program of the Communicable Disease Health
Service Delivery (COMDIS-HSD) Research Consortium,
which includes researchers from both the Chinese University
of Hong Kong, China, and University of Leeds, UK.
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